Entera Bio Ltd. (FRA:5DT)

Market Cap	57.22M -32.6%
Revenue (ttm)	105.69K +25.3%
Net Income	-9.19M
EPS	-0.21
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	550
Average Volume	n/a
Open	1.170
Previous Close	1.154
Day's Range	1.170 - 1.170
52-Week Range	0.884 - 2.660
Beta	n/a
RSI	46.11
Earnings Date	Mar 9, 2026

About Entera Bio

Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis; and has completed Phase 1 clinical trial to treat ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 21
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5DT

Financial Performance

Financial numbers in USD